T1	Concept 62 65	RBD
T2	Action 66 74	targeted
R1	target Arg1:T2 Arg2:T1	
T3	Concept 75 83	SARS-CoV
T4	Concept 84 94	monoclonal
T5	Concept 95 105	antibodies
R2	has-property Arg1:T5 Arg2:T4	
T6	Action 111 116	shown
A1	Negated T6
T7	Concept 121 128	ability
T8	Action 132 136	bind
T9	Action 141 151	neutralize
T10	Concept 152 161	2019-nCoV
R3	subject Arg1:T2 Arg2:T5	
R4	has-part Arg1:T3 Arg2:T5	
R5	subject Arg1:T6 Arg2:T5	
R6	target Arg1:T6 Arg2:T7	
R7	in-context Arg1:T7 Arg2:T8	
R8	in-context Arg1:T7 Arg2:T9	
R9	target Arg1:T8 Arg2:T10	
R10	target Arg1:T9 Arg2:T10	
T11	Concept 189 197	sequence
T13	Concept 206 213	protein
T14	Concept 219 227	SARS-CoV
T15	Concept 245 248	70%
T16	Concept 267 268	S
T12	Concept 201 202	S
T17	Concept 269 276	protein
T18	Concept 282 286	2019
R11	is-a Arg1:T12 Arg2:T13	
R12	is-a Arg1:T16 Arg2:T17	
R13	has-part Arg1:T18 Arg2:T16	
R14	has-part Arg1:T14 Arg2:T12	
T19	Action 249 257	identity
R15	has-property Arg1:T19 Arg2:T15	
R16	in-context Arg1:T11 Arg2:T12	
R17	subject Arg1:T19 Arg2:T11	
R18	target Arg1:T19 Arg2:T16	
T20	Concept 311 319	SARS-Cov
T21	Concept 324 332	MERS-Cov
T22	Concept 338 343	human
T23	Concept 344 355	populations
R19	has-property Arg1:T23 Arg2:T22	
T24	Action 356 362	showed
T25	Concept 363 374	disparities
T26	Concept 378 392	susceptibility
T27	Concept 402 409	viruses
R20	is-a Arg1:T21 Arg2:T27	
R21	is-a Arg1:T20 Arg2:T27	
R22	subject Arg1:T24 Arg2:T23	
R23	target Arg1:T24 Arg2:T26	
R24	has-property Arg1:T26 Arg2:T25	
R25	in-context Arg1:T24 Arg2:T21	
R26	in-context Arg1:T24 Arg2:T20	
T28	Concept 410 421	Gemcitabine
T29	Concept 433 443	originally
T30	Action 444 452	approved
R27	has-property Arg1:T30 Arg2:T29	
T31	Action 457 465	treating
T32	Concept 466 473	certain
T33	Concept 474 479	types
T34	Concept 483 490	cancers
R28	has-property Arg1:T33 Arg2:T32	
R29	in-context Arg1:T33 Arg2:T34	
R30	target Arg1:T31 Arg2:T33	
R31	target Arg1:T30 Arg2:T31	
R32	subject Arg1:T30 Arg2:T28	
T35	Action 516 525	targeting
A2	Uncertain T35
T36	Concept 526 534	SARS-CoV
R33	subject Arg1:T35 Arg2:T28	
R34	target Arg1:T35 Arg2:T36	
T37	Action 540 550	validation
T38	Concept 554 562	previous
T39	Concept 563 571	in vitro
T40	Concept 572 579	studies
R35	has-property Arg1:T40 Arg2:T39	
R36	in-context Arg1:T35 Arg2:T37	
R37	target Arg1:T37 Arg2:T38	
R38	in-context Arg1:T38 Arg2:T40	
T41	Concept 603 606	two
T42	Concept 607 612	sites
T43	Concept 627 632	short
T44	Concept 633 638	helix
T45	Action 613 619	belong
R39	has-property Arg1:T42 Arg2:T41	
R40	subject Arg1:T45 Arg2:T42	
R41	target Arg1:T45 Arg2:T44	
R42	has-property Arg1:T44 Arg2:T43	
T46	Action 639 648	including
R43	in-context Arg1:T46 Arg2:T45	
T47	Reference 649 656	changes
T48	Action 662 672	were found
T49	Concept 676 681	human
T50	Concept 682 690	SARS-CoV
R44	in-place Arg1:T48 Arg2:T50	
R45	in-context Arg1:T50 Arg2:T49	
R46	subject Arg1:T48 Arg2:T47	
R47	target Arg1:T46 Arg2:T47	
